{"title":"Safety and Efficacy of Nebulised Anti-Inflammatory Solution of Alkaline Hypertonic Ibuprofen (AHI) for Treatment of SARS-Cov-2 Infection: A Compassionate Study with a Comparator Arms","authors":"","doi":"10.31488/ejrm.132","DOIUrl":"https://doi.org/10.31488/ejrm.132","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73987201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M O Sowho, P Galiatsatos, M Guzman, N N Hansel, J C Jun, E R Neptune, P Biselli, J P Kirkness
Introduction: Nasal high-flow therapy (HFT) has been shown to improve daytime breathing mechanics in healthy adults as well as the lung function and quality of life in chronic obstructive pulmonary disease (COPD) patients.
Method: We hypothesized that improved breathing mechanics with HFT may further reduce minute ventilation (i.e. decreased work of breathing) during sleep in patients with COPD. In COPD participants we examined the dose effect of HFT (within night randomization of HFT level; 0, 10, 20 and 30L/min) on minute ventilation, oxyhemaglobin saturation and transcutaneous carbon dioxide during wake and sleep. We assessed overnight polysomnography with and without HFT on two separate nights. Paired t-tests were used to compare overnight sleep quality with and without HFT. The association between ventilatory variables and HFT level was assessed using regression analysis.
Results: During sleep, HFT decreased minute ventilation by 0.63±0.02L/min per 10L/min nasal airflow by reducing tidal volume (37±6mL per 10L/min; p<0.001) without affecting respiratory rate (p=0.9) or arterial CO2 (p=0.7). In contrast, during wakefulness reductions in minute ventilation (0.85±0.04L/min per 10L/min) was due to respiratory rate reduction along with prolongation in expiratory time.
Conclusion: The reduction in minute ventilation is greater with higher dead-space volumes (r=0.50; p<0.02) and during wakefulness suggesting that ventilatory responses to HFT are mediated through a reduction in dead-space ventilation. The reduction in ventilation in response to HFT is large enough to reduce respiratory loads. Reducing respiratory loads may avert muscle fatigue, preserve respiratory function, or prevent development of respiratory failure.
{"title":"The Effect of Nasal High Flow Therapy on Minute Ventilation in Chronic Obstructive Pulmonary Disease.","authors":"M O Sowho, P Galiatsatos, M Guzman, N N Hansel, J C Jun, E R Neptune, P Biselli, J P Kirkness","doi":"10.31488/ejrm.113","DOIUrl":"https://doi.org/10.31488/ejrm.113","url":null,"abstract":"<p><strong>Introduction: </strong>Nasal high-flow therapy (HFT) has been shown to improve daytime breathing mechanics in healthy adults as well as the lung function and quality of life in chronic obstructive pulmonary disease (COPD) patients.</p><p><strong>Method: </strong>We hypothesized that improved breathing mechanics with HFT may further reduce minute ventilation (i.e. decreased work of breathing) during sleep in patients with COPD. In COPD participants we examined the dose effect of HFT (within night randomization of HFT level; 0, 10, 20 and 30L/min) on minute ventilation, oxyhemaglobin saturation and transcutaneous carbon dioxide during wake and sleep. We assessed overnight polysomnography with and without HFT on two separate nights. Paired t-tests were used to compare overnight sleep quality with and without HFT. The association between ventilatory variables and HFT level was assessed using regression analysis.</p><p><strong>Results: </strong>During sleep, HFT decreased minute ventilation by 0.63±0.02L/min per 10L/min nasal airflow by reducing tidal volume (37±6mL per 10L/min; p<0.001) without affecting respiratory rate (p=0.9) or arterial CO<sub>2</sub> (p=0.7). In contrast, during wakefulness reductions in minute ventilation (0.85±0.04L/min per 10L/min) was due to respiratory rate reduction along with prolongation in expiratory time.</p><p><strong>Conclusion: </strong>The reduction in minute ventilation is greater with higher dead-space volumes (r=0.50; p<0.02) and during wakefulness suggesting that ventilatory responses to HFT are mediated through a reduction in dead-space ventilation. The reduction in ventilation in response to HFT is large enough to reduce respiratory loads. Reducing respiratory loads may avert muscle fatigue, preserve respiratory function, or prevent development of respiratory failure.</p>","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"3 1","pages":"172-177"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428779/pdf/nihms-1831282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9340472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inspiratory Muscle Training with an Electronic Device to Facilitate Weaning Ventilatory of a Patient with COVID-19","authors":"","doi":"10.31488/ejrm.111","DOIUrl":"https://doi.org/10.31488/ejrm.111","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75092563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evidence-Based Practice for Care of Preterm Infants Receiving Non-Invasive Ventilation (Clinical Trials identifier: NCT04165382)","authors":"","doi":"10.31488/ejrm.110","DOIUrl":"https://doi.org/10.31488/ejrm.110","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88232724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Methamphetamine, one of the most commonly used illegal stimulants worldwide, has been recently upgraded to the definite category in association with development of pulmonary arterial hypertension (PAH). Though its incidence and prevalence in the general population and among active methamphetamine users are unknown, with the epidemic surge of methamphetamine use, we are bound to see more cases of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH). Neither basic pathophysiology nor optimal treatment strategy has been well studied for Meth-APAH, which has been shown to have worse outcomes when compared with idiopathic PAH. Extrapolating experience from other conditions associated with methamphetamine, cessation of methamphetamine use remains front and center of the treatment goals of Meth-APAH, to be complemented by other pharmacological, behavioral and psychosocial therapies in a multidisciplinary approach in dealing with this complex and highly morbid condition.
{"title":"Current State and Understanding of Methamphetamine-associated Pulmonary Arterial Hypertension","authors":"Raymond Xu, Susan X. Zhao","doi":"10.31488/ejrm.112","DOIUrl":"https://doi.org/10.31488/ejrm.112","url":null,"abstract":"Methamphetamine, one of the most commonly used illegal stimulants worldwide, has been recently upgraded to the definite category in association with development of pulmonary arterial hypertension (PAH). Though its incidence and prevalence in the general population and among active methamphetamine users are unknown, with the epidemic surge of methamphetamine use, we are bound to see more cases of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH). Neither basic pathophysiology nor optimal treatment strategy has been well studied for Meth-APAH, which has been shown to have worse outcomes when compared with idiopathic PAH. Extrapolating experience from other conditions associated with methamphetamine, cessation of methamphetamine use remains front and center of the treatment goals of Meth-APAH, to be complemented by other pharmacological, behavioral and psychosocial therapies in a multidisciplinary approach in dealing with this complex and highly morbid condition.","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90544707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Crazy-Paving Pattern: A Rare Case of Autoimmune Pulmonary Alveolar Proteinosis (PAP) with Positive Anti-GM-CSF Antibody Following Cryptococcal Infection in an otherwise Healthy Individual and Review of Literature","authors":"","doi":"10.31488/ejrm.116","DOIUrl":"https://doi.org/10.31488/ejrm.116","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90916954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Use of End-Tidal CO2 as a Screening Tool in Patients with Pulmonary Embolism","authors":"","doi":"10.31488/ejrm.117","DOIUrl":"https://doi.org/10.31488/ejrm.117","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82010973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Use of Noninvasive Positive-Pressure Ventilation to Prevent Extubation Failure: A Concise Review","authors":"","doi":"10.31488/ejrm.120","DOIUrl":"https://doi.org/10.31488/ejrm.120","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79516128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evolution of a Pivotal Clinical Study to Evaluate Extracorporeal Photopheresis for Refractory Bronchiolitis Obliterans","authors":"","doi":"10.31488/ejrm.114","DOIUrl":"https://doi.org/10.31488/ejrm.114","url":null,"abstract":"","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74421143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher R. Lupfer, Riley A Nadler, Ronald Amen, Alain Martin
Background: To combat the continuing COVID-19 pandemic, and to treat the symptoms in Long COVID patients safe, effective, and inexpensive treatments are needed. Patients recovering from severe COVID-19 are at serious risk of de veloping pulmonary fibrosis. Conversely, patients with pulmonary fibrosis have an increased risk and susceptibility to COVID-19 infection, demonstrating the need to treat both. Design: Three separate clinical trials were conducted 1) in COVID-19 infected patients, 2) in Long COVID patients, and 3) in patients with Pulmonary Fibrosis to determine the effi cacy of N115, a sodium pyruvate based nasal spray. Patient symptoms, vital signs and respiratory function were evaluated compared to a placebo control or a no treatment baseline control. Findings: During active COVID-19 infection, N115 de creased viral titers and produced a significant improvement over saline in coughing/sneezing and fatigue. In Long COVID patients, N115 significantly reduced headache, coughing/sneezing and increased SaO2 levels (decreased hypoxemia) and improved breathing (dyspnea). In patients with Pulmonary Fibrosis, there was a significant improvement in all lung func -tions, compared to baseline, as determined by changes in SaO2, FVC, FEV1, PEF, and FEV1/FVC ratio. Conclusions: N115 is safe and effective at reducing symptoms of active COVID-19 infection and improves disease condition in Long COVID patients. Furthermore, N115 significantly improves lung function in Pulmonary Fibrosis patients. As COVID-19 and Pulmonary Fibrosis are associated with each other, our clinical research demonstrates that N115 is a promising treat ment for both and adds to the current 19 human clinical trials where N115 has shown efficacy in thousands of patients, regardless of the etiology of the lung disease (COPD, CF, allergic rhinitis, sinusitis, the flu, COVID-19 infected patients, Long COVID and patients with Fibrosis).
{"title":"Inhalation of Sodium Pyruvate to Reduce the Symptoms and Severity of Respiratory Diseases Including COVID-19, Long COVID, and Pulmonary Fibrosis","authors":"Christopher R. Lupfer, Riley A Nadler, Ronald Amen, Alain Martin","doi":"10.31488/ejrm.121","DOIUrl":"https://doi.org/10.31488/ejrm.121","url":null,"abstract":"Background: To combat the continuing COVID-19 pandemic, and to treat the symptoms in Long COVID patients safe, effective, and inexpensive treatments are needed. Patients recovering from severe COVID-19 are at serious risk of de veloping pulmonary fibrosis. Conversely, patients with pulmonary fibrosis have an increased risk and susceptibility to COVID-19 infection, demonstrating the need to treat both. Design: Three separate clinical trials were conducted 1) in COVID-19 infected patients, 2) in Long COVID patients, and 3) in patients with Pulmonary Fibrosis to determine the effi cacy of N115, a sodium pyruvate based nasal spray. Patient symptoms, vital signs and respiratory function were evaluated compared to a placebo control or a no treatment baseline control. Findings: During active COVID-19 infection, N115 de creased viral titers and produced a significant improvement over saline in coughing/sneezing and fatigue. In Long COVID patients, N115 significantly reduced headache, coughing/sneezing and increased SaO2 levels (decreased hypoxemia) and improved breathing (dyspnea). In patients with Pulmonary Fibrosis, there was a significant improvement in all lung func -tions, compared to baseline, as determined by changes in SaO2, FVC, FEV1, PEF, and FEV1/FVC ratio. Conclusions: N115 is safe and effective at reducing symptoms of active COVID-19 infection and improves disease condition in Long COVID patients. Furthermore, N115 significantly improves lung function in Pulmonary Fibrosis patients. As COVID-19 and Pulmonary Fibrosis are associated with each other, our clinical research demonstrates that N115 is a promising treat ment for both and adds to the current 19 human clinical trials where N115 has shown efficacy in thousands of patients, regardless of the etiology of the lung disease (COPD, CF, allergic rhinitis, sinusitis, the flu, COVID-19 infected patients, Long COVID and patients with Fibrosis).","PeriodicalId":72981,"journal":{"name":"European journal of respiratory medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82037293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号